

Based on the detailed technical and fundamental report provided for **LUPIN.NS** (generated date: 2026-01-10), here is the positional trading analysis.

Step 1: Audit the Data

- Data Present:**
  - Multi-timeframe price charts (Weekly, Daily, 15m).
  - Moving Averages (EMA 20, 50, 200) and crossover status.
  - Momentum Indicators (RSI, MACD, Supertrend).
  - Volatility Analysis (Bollinger Bands, ATR, Squeeze setups).
  - Relative Strength (RS) metrics against the Pharma benchmark.
  - Basic Fundamental snapshot (Revenue/Profit trends).
- Data Missing:**
  - Real-time Order Book/Market Depth (for precise intraday entry).
  - Detailed Sector Breadth (broader Pharma index performance is referenced but not detailed beyond RS).
- Confidence Level:** **High**. The report provides a comprehensive technical view, combining trend, momentum, and volatility data sufficient for a swing trading decision. *Note: The analysis treats the report date (Jan 10, 2026) as "Today" for the purpose of the setup.*

---

Step 2: Analyze the Setup

- Price Structure & Trend:** The stock is in a confirmed **Strong Uptrend**. Price (2182) is trading above the EMA 20 (2123), EMA 50 (2079), and EMA 200 (2008). This "stacked" formation is the ideal bullish structure for positional trades. The stock recently consolidated and has reclaimed the short-term moving averages.
- Momentum Confluence:**
  - MACD:** The MACD is bullish with the line (27.53) above the signal (20.41), and momentum is explicitly listed as "Strengthening."
  - Supertrend:** The daily Supertrend triggered a BUY signal on Nov 12, 2025, and remains green with support at 2097.
  - RSI:** At 63.95, the RSI is in the bullish zone (40-80) with room to run before becoming overbought.
- Volatility & Volume:**
  - Squeeze Breakout:** Page 14 highlights a "BB Squeeze + ATR Contraction (Bullish Breakout)." This is a high-probability setup indicating an expansion of range to the upside after a period of consolidation.
  - Volume:** Current volume (929k) is tracking above the 20-day average (713k), supporting the breakout validity.
  - Relative Strength Caution:** The RS Score is 53.1/100, and the classification is "Weakening Leader." While the stock is trending up, it is not currently outperforming the Pharma index aggressively. This suggests the stock will likely move with the market/sector rather than creating alpha independently.

---

Step 3: Formulate the Recommendation

**Verdict:** **YES**

The technical confluence is strong. The combination of a volatility squeeze breakout, price trading above all key EMAs, and supportive volume suggests a continuation of the primary trend toward previous highs. The risk is defined by the 50 EMA and Supertrend support levels.

**Entry Price:** **INR 2182 - INR 2190** (Enter at Current Market Price. The breakout is active; waiting for a deep

pullback might result in a missed opportunity given the momentum).

\* **Stop Loss**: **INR 2070** (Daily Closing Basis).

\* **Rationale**: This places the stop just below the 50 EMA (2079) and the Supertrend Support (2097). A close below this level invalidates the intermediate uptrend structure.

\* **Take Profit**: **INR 2400 - INR 2450**

\* **Rationale**: The primary target is the re-test of the recent swing high (visible on the 3-year chart around 2400). This offers an approximate **10% upside**, fitting the mandate. A secondary extension could reach 2500 if sector momentum improves.

**Risk/Reward Profile**:

\* Risk: ~5.1%

\* Reward: ~10% to 12%

\* Ratio: ~1:2 (Acceptable for intermediate swing).

## # News & Analyst Targets

Hello. Acting as your stock research analyst, I have compiled the latest news, brokerage sentiment, and price targets for **Lupin Limited**.

### 1) Latest News for Lupin (Week of Jan 5-10, 2026)

The most significant activity for Lupin this week has been driven by market momentum and spillover from major strategic announcements made just before the new year.

\* **Stock Rally & Technical Breakout**: Lupin shares witnessed a strong rally this week (Jan 6-8), hitting intraday highs and outperforming the broader Nifty Pharma index. The stock surged ~3-4% in individual sessions, driven by heavy trading volumes and positive sentiment surrounding its recent product deals.

\* **Exclusive Licensing Deal with Gan & Lee**: In a major strategic move announced at the very end of December (and impacting sentiment this week), Lupin signed an exclusive licensing, supply, and distribution agreement with China-based **Gan & Lee Pharmaceuticals**.

\* **The Drug**: **Bofanglutide**, a novel once-every-two-weeks GLP-1 receptor agonist injection for diabetes and obesity.

\* **Impact**: This positions Lupin to compete in the high-growth "weight loss" (GLP-1) market in India, challenging potential entrants like Novo Nordisk's Wegovy and Eli Lilly's Zepbound.

\* **Acquisition Update (Visufarma)**: Lupin provided an update regarding its acquisition of Dutch specialty pharma company **VISUfarma B.V.**, extending the timeline for closing the deal. This acquisition is part of Lupin's strategy to expand its presence in the ophthalmic sector in Europe.

\* **Leadership Change**: The company announced the appointment of Mr. Anand Kripalu as an Additional Director (Non-Executive, Independent) effective February 1, 2026.

### 2) Upgrade/Downgrade from Brokerages

Most major brokerage updates were issued following the Q2 earnings in November 2025, but the sentiment remains actively bullish into January 2026.

\* **Nomura** (**Bullish**): Maintains a **Buy** rating and recently raised its target price to **INR 2,580**. They cite strong momentum in the US business and a recovery in India growth as key drivers.

\* **JPMorgan (Overweight)**: Remains one of the most bullish brokers, maintaining an **Overweight** rating with a target of **INR 2,600**. They highlight margin expansion and a strong pipeline of complex generics.

\* **Investec (Upgrade)**: Upgraded the stock to **Buy** (from Hold) with a target of **INR 2,265**, specifically noting the potential of the GLP-1 opportunity in India.

\* **CLSA**: Upgraded to **Outperform** with a target of **INR 2,400**, driven by better-than-expected US sales from products like **gSpiriva**.

### 3) Other News Impacting Lupin

\* **US Investment (\$250M)**: While announced in Q4 2025, the market continues to digest Lupin's commitment to

invest **\*\*\$250 million\*\*** in a new manufacturing facility in **\*\*Coral Springs, Florida\*\***. This site will produce critical respiratory medicines, insulating Lupin from potential import tariffs and strengthening its US supply chain.

\* **\*\*US FDA Approvals:\*\*** Lupin recently received tentative US FDA approval for **\*\*Siponimod Tablets\*\*** (generic for Novartis's *\*Mayzent\**, used for Multiple Sclerosis) and **\*\*Sitagliptin/Metformin\*\*** (generic for *\*Janumet\**). These approvals strengthen its complex generic pipeline for FY27.

\* **\*\*Sector Trends:\*\*** The Nifty Pharma index has been hitting 52-week highs in January 2026, creating a "rising tide" that is lifting Lupin alongside peers like Sun Pharma and Glenmark.

---

### **\*\*4) Latest Analyst Targets\*\***

The following table summarizes the most recent price targets from major brokerage firms. The consensus sentiment is currently **\*\*Accumulate/Buy\*\***.

Brokerage Firm	Rating	Target Price (INR )	Date of Report	Key Rationale
:---	:---	:---	:---	:---
<b>**JPMorgan**</b>	Overweight	<b>**2,600**</b>	Nov 10, 2025	Strong Q2 beat, EBITDA margin guidance raised to 25-26%.
<b>**Nomura**</b>	Buy	<b>**2,580**</b>	Nov 11, 2025	US sales momentum and India business recovery; valuation attractive.
<b>**CLSA**</b>	Outperform	<b>**2,400**</b>	Nov 11, 2025	US revenue +47% YoY; strong traction in <i>*gSpiriva*</i> (respiratory).
<b>**Deven Choksey**</b>	Buy	<b>**2,404**</b>	Nov 13, 2025	Margin expansion and niche product launches.
<b>**Investec**</b>	Buy	<b>**2,265**</b>	Sep 12, 2025	Capitalizing on GLP-1 therapy opportunity in India.
<b>**ICICI Direct**</b>	Buy	<b>**2,275**</b>	Nov 11, 2025	Sustained momentum in North America; regulatory compliance improved.
<b>**Geojit BNP**</b>	Buy	<b>**2,225**</b>	Nov 25, 2025	Healthy product pipeline and improved operational efficiency.
<b>**Motilal Oswal**</b>	Neutral	<b>**2,100**</b>	Nov 08, 2025	Valuation concerns despite strong earnings; awaits further scale-up.
<b>**BofA Securities**</b>	Neutral	<b>**2,030**</b>	Nov 10, 2025	Margins strong but current price prices in most positives.

**\*\*Analyst Consensus:\*\*** ~INR 2,328 (Upside potential of approx. 6-7% from current levels of INR 2,180).


# Stock Detailed Analysis Report

**LUPIN.NS**

Current Price: ₹2182.20

Generated: 2026-01-10 10:19

# LUPIN.NS - 3 Year Daily Price Chart



# Long-term Fundamental Analysis (4 Years)

Metric	Is Growing?	Accelerating?	1Y Growth	3Y CAGR
Revenue	Yes	Yes	12.90%	11.08%

# Short-term Fundamental Analysis (6 Quarters)

Metric	Is Growing?	Recent QoQ	Avg QoQ
Revenue	Yes	10.81%	2.93%
Net Income	Yes	57.80%	13.71%
ROE	No	-17.62%	-17.62%
EPS	Yes	0.27%	3.32%

# LUPIN.NS - Relative Strength Analysis

## == OVERVIEW ==:

Benchmark Index:	^CNXPHARMA
Sector:	Pharma
Classification:	<b>Weakening Leader</b>
RS Score:	53.1/100
:	

## == RS RATIOS ==:

1M RS:	<b>1.037 [Leader]</b>
3M RS:	<b>1.055 [Leader]</b>
6M RS:	<b>1.129 [Leader]</b>
1Y RS:	<b>1.009 [Leader]</b>
:	

## == TURNAROUND ANALYSIS ==:

Turnaround Status:	<b>Not Detected</b>
:	


## SIGNAL CRITERIA::

× Emerging RS:	<b>Not accelerating</b>
× Medium-term Lagging:	<b>Not lagging</b>
× Performance Improving:	<b>Not improving</b>


# Relative Strength Analysis: LUPIN.NS vs ^CNXPBARMA

## Classification: Weakening Leader


Price Performance Comparison (Normalized)



RS Ratio Trends (Multiple Timeframes)



RS Composite Score Timeline






## LUPIN.NS - EMA Crossover Summary

EMA 20:	2123.84
EMA 50:	2079.46
EMA 200:	2008.13
Trend Status:	Strong Uptrend
Golden Cross Date:	2025-11-13 00:00:00+05:30
Golden Cross Price:	2052.90

LUPIN.NS EMA Crossover Analysis



## LUPIN.NS - Bollinger Bands Summary

<b>Current Price:</b>	2182.20
<b>Upper Band:</b>	2194.09
<b>Middle Band (SMA 20):</b>	2120.42
<b>Lower Band:</b>	2046.74
<b>%B:</b>	0.9193
<b>Band Width:</b>	0.0695
<b>Status:</b>	Upper Half
<b>Signal:</b>	None
<b>Recent Signal 1:</b>	<b>Sell Signal at 2025-11-17 00:00:00+05:30</b>


LUPIN.NS Bollinger Bands (20, 2) Analysis



## LUPIN.NS - Supertrend Summary

Status:	UPTREND (Buy)
Supertrend Value:	2097.60
Signal Identified On:	2025-11-12


Supertrend Analysis for LUPIN.NS (Period: 14, Multiplier: 3.0, Interval: 1d)




## LUPIN.NS - MACD Summary

MACD Line:	27.53
Signal Line:	20.41
Histogram:	7.11
Trend:	<b>Bullish</b>
Momentum:	<b>Strengthening</b>
Signal:	None
Divergences Detected:	1
└ Bearish Divergence:	Date: 2026-01-07 00:00:00+05:30, Price: 2214.30

LUPIN.NS Price



LUPIN.NS MACD (12, 26, 9)








# LUPIN.NS - Volatility Squeeze Summary

BB Width:	0.0695
ATR:	36.4571
Total Signals:	46
Signal 1:	BB Squeeze + ATR Contraction at 2025-12-31 00:00:00+05:30 (Pr
Signal 2:	BB Squeeze + ATR Contraction at 2026-01-01 00:00:00+05:30 (Pr
Signal 3:	BB Squeeze + ATR Contraction at 2026-01-02 00:00:00+05:30 (Pr
Signal 4:	BB Squeeze + ATR Contraction at 2026-01-05 00:00:00+05:30 (Pr
Signal 5:	BB Squeeze + ATR Contraction (Bullish Breakout) at 2026-0


# LUPIN.NS - Volatility Squeeze Analysis



## LUPIN.NS - RSI-Volume Summary

<b>Current RSI:</b>	63.95
<b>Current Volume:</b>	929502
<b>Volume MA 20:</b>	713856
<b>Bullish Divergences:</b>	0
<b>Bearish Divergences:</b>	3
<b>Bearish Div 1:</b>	Date: 2025-04-28 00:00:00+05:30, Price: 2092.39
<b>Bearish Div 2:</b>	Date: 2025-12-22 00:00:00+05:30, Price: 2126.30

# LUPIN.NS RSI-Volume Divergence Analysis



## Multi-Timeframe Supertrend Analysis

Timeframe	Status	Value	Last Price	Signal Date
1 Week	UPTREND (Buy)	1988.75	2182.2	2025-12-01
1 Day	UPTREND (Buy)	2097.6	2182.2	2025-11-12
15 Min	UPTREND (Buy)	2163.44	2178.0	2026-01-09

## Multi-Timeframe MACD Analysis

Timeframe	Trend	Momentum	Signal
1 Week	Bullish	Strengthening	No Signal
1 Day	Bullish	Strengthening	No Signal
15 Min	Bullish	Weakening	No Signal

LUPIN.NS - 1 Week (Candlestick + EMAs)




LUPIN.NS - 1 Day (Candlestick + EMAs)



LUPIN.NS - 15 Min (Candlestick + EMAs)



Trendlyne Snapshot - LUPIN\_main



Lupin Key Metrics

Preset Metrics

ROE Ann. %19.1

Broker Average Target2,328

Market Capitalization99,682.6

Price to Book

High in Industry

6.68% upside

High in Industry

Above Industry Median

DVM

Key Metrics

Price Chart

Forecaster

Financials

Technicals

Shareholding

Deals

Documents

Corporate actions

Company Profile

# Trendlyne Snapshot - LUPIN\_forecaster

MarketsSTARFOLIOAlertsF&O MF Reports ScreenersSubscribeSuperstarsPortfolioWatchlistInsider TradesResultsData DownloaderMore

Search Stock, IPO, MF

India

A

MARKETS / SECTOR: PHARMACEUTICALS & BIOTECHNOLOGY / INDUSTRY: PHARMACEUTICALS / LUPIN LTD.

Lupin Ltd. ⓘ  
NSE: LUPIN | BSE: 500257  
Strong Performer, Getting Expensive ⓘ  
In 1 Starfolio Basket

2182.20 -8.70 (-0.40%)  
Near 52W High of ₹2262.60

939.3K NSE+BSE Volume  
NSE 09 Jan, 2026 3:31 PM (IST)

WatchlistPortfolioAlertMy NotesTRADE STOCK

OverviewFORECASTERSTOCK REPORTBuy Sell ZoneF&OFinancialsNewsReportsTechnicalsShareholdingDealsCorporate ActionsAlertsAbout

## Lupin - LUPIN - stock price prediction, stock forecast, target price, analyst ratings from 37 analysts

Lupin has a share price target of Rs 2291, revenue growth forecast of 14.4%, and profit growth estimate of 36.6% for FY26, based on top 37 analyst calls.

### Lupin FORECASTER - Analyst Estimates ⓘ

FORECASTER DASHBOARD →

